RET (L730M)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.L730M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pralsetinib | 99.7% | 0.3% | 93.43 |
| 2 | Alpelisib | 99.2% | 0.8% | 97.22 |
| 3 | Fedratinib | 99.1% | 0.9% | 96.21 |
| 4 | Entrectinib | 99.0% | 1.0% | 93.69 |
| 5 | Tenalisib | 97.4% | 2.6% | 97.98 |
| 6 | Ripretinib | 97.1% | 2.9% | 92.95 |
| 7 | Sorafenib | 96.9% | 3.1% | 96.72 |
| 8 | Vandetanib | 96.9% | 3.1% | 95.74 |
| 9 | Sunitinib | 96.8% | 3.2% | 91.73 |
| 10 | Selpercatinib | 95.5% | 4.5% | 96.72 |
| 11 | Quizartinib | 94.4% | 5.6% | 99.50 |
| 12 | Tivozanib | 94.0% | 6.0% | 92.42 |
| 13 | Gilteritinib | 93.7% | 6.3% | 88.97 |
| 14 | Futibatinib | 92.0% | 8.0% | 98.48 |
| 15 | Apatinib | 91.0% | 9.0% | 97.73 |
| 16 | Repotrectinib | 87.8% | 12.2% | 84.21 |
| 17 | Erdafitinib | 85.0% | 15.0% | 95.71 |
| 18 | Canertinib | 72.9% | 27.1% | 96.49 |
| 19 | Erlotinib | 33.9% | 66.1% | 99.75 |
| 20 | Pirtobrutinib | 33.7% | 66.3% | 99.49 |
| 21 | Umbralisib | 30.9% | 69.1% | 98.74 |
| 22 | Defactinib | 29.4% | 70.6% | 92.68 |
| 23 | Upadacitinib | 28.9% | 71.1% | 97.98 |
| 24 | Deucravacitinib | 27.2% | 72.8% | 98.99 |
| 25 | Capivasertib | 20.6% | 79.4% | 96.48 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pralsetinib | 99.7% | 100.0% | -0.3% |
| Alpelisib | 99.2% | 99.6% | -0.5% |
| Fedratinib | 99.1% | 99.9% | -0.8% |
| Entrectinib | 99.0% | 99.6% | -0.6% |
| Tenalisib | 97.4% | 98.5% | -1.1% |
| Ripretinib | 97.1% | — | — |
| Sorafenib | 96.9% | 94.0% | +3.0% |
| Vandetanib | 96.9% | 98.6% | -1.7% |
| Sunitinib | 96.8% | 97.2% | -0.4% |
| Selpercatinib | 95.5% | 100.0% | -4.5% |
| Quizartinib | 94.4% | — | — |
| Tivozanib | 94.0% | 99.7% | -5.7% |
| Gilteritinib | 93.7% | 100.0% | -6.3% |
| Futibatinib | 92.0% | 97.7% | -5.7% |
| Apatinib | 91.0% | — | — |
| Repotrectinib | 87.8% | — | — |
| Erdafitinib | 85.0% | 94.7% | -9.6% |
| Canertinib | 72.9% | — | — |
| Erlotinib | 33.9% | — | — |
| Pirtobrutinib | 33.7% | — | — |
| Umbralisib | 30.9% | — | — |
| Defactinib | 29.4% | — | — |
| Upadacitinib | 28.9% | — | — |
| Deucravacitinib | 27.2% | — | — |
| Capivasertib | 20.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_thyroid | Thyroid | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.8ms